Trial Profile
A Phase II Study of Bevacizumab,Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Feb 2018
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Temozolomide
- Indications Glioblastoma; Glioma
- Focus Adverse reactions; Therapeutic Use
- 24 Mar 2017 Status changed from active, no longer recruiting to completed.
- 25 Jul 2016 Planned End Date changed from 1 Oct 2016 to 1 Oct 2017.
- 25 Jul 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Oct 2017.